Staci Bush
Durham,NC
Summary
Dynamic biotech leader with extensive expertise in public health and medical strategy, skilled in fostering strategic alliances among medical professionals, researchers, and governmental entities both domestically and internationally. Proven track record in advancing new products and initiatives through targeted messaging, rigorous scientific research, and impactful dialogue. Committed to enhancing medical strategy execution and disciplined project management, driving collaboration that transcends industry boundaries to maximize utilization and improve health outcomes. Passionate about leveraging diverse knowledge to create innovative solutions that address pressing healthcare challenges.
Overview
19
19
years of professional experience
Work History
Senior Director, Virology Scientific Collaboration
Gilead Sciences
01.2023 - Current
- Drove the development of the first pan-virology Plan of Action and strategy, across HIV treatment and prevention.
- Lead the strategic and tactical conference planning for virology including HIV, Liver hepatitis, PBC, and COVID to external stake holders, and internal cross-functional partners.
- Worked cross functionally with Business Conduct, Clinical, Regulatory, Managed Markets, Public Affairs, and Government Affairs leadership
- Provided oversight of high priority initiatives which require change management support, strategic thinking, and alignment of cross-functional leaders and teams.
- Developed and launched US medical affairs conference sponsorship and education strategy
- Led cross-functional teams to implement strategic initiatives that enhanced operational efficiency.
- Developed and executed comprehensive business strategies to drive growth and market expansion.
- Oversaw budget management, ensuring alignment with organizational goals and financial sustainability.
- Mentored senior leaders, fostering talent development and succession planning within the organization.
- Analyzed market trends to inform strategic decision-making and competitive positioning.
- Established performance metrics to evaluate departmental success and drive continuous improvement initiatives.
- Collaborated with stakeholders to align project goals with organizational objectives, enhancing stakeholder engagement.
- Optimized project timelines by effectively delegating tasks and prioritizing workload among team members.
- Developed strong relationships with key industry partners, fostering collaboration and mutual growth opportunities.
- Cultivate and maintain strategic relationships with US medical societies, NGOs, and advocacy groups.
- Collaborate closely with Public Affairs on external leadership activities and internal health equity initiatives.
Senior Medical Director, HIV Prevention
ViiV Healthcare
12.2020 - 03.2022
- Developed a MA strategy to support the FDA approval and launch readiness for CAB for PrEP, the first long-acting injectable drug for HIV prevention.
- Guided the development of proper training tools for field MSLs, Regional Directors, and Commercial teams.
- Formulated and aligned messaging across Commercial, Public Affairs, and Global Medical Teams.
- Oversaw promotional review, advisory boards, and publication dissemination.
- North America Medical Affairs (NAMA)
Global Executive Director for PrEP, Medical Affairs
Gilead Sciences
04.2020 - 12.2020
- Developed and executed global and US HIV Prevention Medical Affairs Plan of Action
- Co-chaired HIV Prevention Indication Leadership Team with Global Commercial Product Strategy to develop the HIV Prevention Indication Strategic Plan
- Supported pipeline development strategy
- Collaborated with global, external organizations including non-profits, businesses and government agencies to create mutually beneficial partnerships.
- Developed strategic partnerships with key public health stakeholders to expand the organization's reach and influence to raise awareness and support.
- Advocated for policy changes at both US and international levels to support the organization's public health goals and objectives.
Global Senior Director, Medical Affairs
Gilead Sciences
02.2019 - 04.2020
- Contributed to the development of Global, regional and national medical plans of action, and ensuring their national implementation.
- Delivered expertise to inform business decision making supporting the planning and execution of Gilead’s product Launch
- Developed and executed long-term strategic plans aligned with organizational goals and market trends.
- Provided medical insight and competitive intel for commercial readiness in US markets
- Led digital campaign in South Africa in partnership with PEPFAR, Elton John Foundation, and others
- Monitor launch effectiveness and impact on patient experience.
Global Director for Medical Education and Learning & Development, Access Operations and Emerging Markets
Gilead Sciences
08.2017 - 02.2019
- Led a lean division in ongoing sales strategy and team development to produce $466M in sales on a $800K budget for a leading biopharmaceutical company.
- Launched HIV, HCV, HBV, and anti-fungal products in 140 low and middle income countries; influenced governments to achieve a dramatic shift for the prevention of AIDS and the elimination of HIV and HCV.
- Expedited introduction of key products into world markets as a preferred partner for PEPFAR, UNAIDS, Elton John Foundation and others, securing business via face-to-face relationships
- Grew foreign markets in 6 months to reach 11.5 million HIV patients (+15%) and 1.1 million HIV patients (+20%) by leading the development of global medical and sales trainings for Africa, Latin America, parts of Asia and Russian Federation.
- Launched sales competencies and sales coaching model programs that prepared reps for the competitive sales landscape. Analyzed successful strategies and replicated successes.
- Penetrated new markets in Mexico and Brazil by initiating the first analysis of training needs for sales teams, maintaining market dominance.
- Created HIV, HCV and HBV marketing campaign for the First Ladies Organizations of Africa and the Caribbean (OAFLA and SCLAN) in 5 languages that prepared them for high-level conversations at the UN and influenced adoption of new public health programs.
Director, Medical Affairs, Truvada and Truvada for PrEP
Gilead Sciences
05.2015 - 08.2017
- Created 523% increase in drug utilization by pioneering sales strategies, creating sales teams, conducting market research, building global alliances, and identifying key influencers, resulting in an HIV reduction of 18% in the US from 2012-2016 and positioning Gilead as the innovator of HIV prevention.
- Created branded and unbranded promotional materials and awareness campaign.
- Increased product advocacy without a sales team by forging relationships with CDC, AMA, Assoc. of OBGYNs, AIDs Coalition, Planned Parenthood and more, creating an influential alliance to promote drug efficacy.
- Lead up planning culminating in the development of data which persuaded CDC to institute a $200M increase in AIDS service organization funding for HIV prevention in minority populations.
- Oversaw Medical Affairs support tools including training decks and manuscripts
Associate Director, Medical Affairs
Gilead Sciences
05.2013 - 05.2015
- Worked to change the HIV prevention landscape by traveling worldwide to speak on core scientific evidence that supported Truvada for PrEP’s efficacy and results. Cut through regulatory, medical, and international skepticism to reverse opposition and position the product to meet a $1B revenue forecast that spawned a new division.
- Built up knowledge database by managing medical science communications for HIV portfolio that included Atripla, Viread, Emtriva, Truvada and Truvada for PrEP.
- Cleared major hurdle to increase market access by working with FDA to fulfill post marketing requirements.
- Utilized network to identify key opinion leaders (KOLs) for phase III and IV investigators and enrollment sites. Developed KOLs as subject matter experts at professional venues, reinforcing marketing and product positioning.
Medical Science Liaison
Gilead Sciences
05.2010 - 05.2013
- Grew 10-Midwest-state market for a portfolio of HIV drugs by prioritizing targeted agencies, providers, and market influencers, exceeding target goal at 170%. Leveraged scientific knowledge and persuasion skills to shift early adoption of products away from traditional markets.
Medical Director
Harrow Health Center
01.2010 - 06.2010
- Managed operations and Physician Assistant duties for 2 area clinics and increased their scope of practice and revenue.
Physician Assistant
Swedish Covenant Hospital
03.2009 - 01.2010
- Medical provider for Acute Inpatient Rehabilitation Unit focused on physical and occupational therapy, physiatry, sports-related injuries, orthopedic trauma, intervention for paralysis, and pain management.
HIV Director
Clinical Care Options
04.2008 - 01.2009
- Produced $13M in sales through the development of world-class continuing medical education (CMEs) related to HIV topics.
Medical Science Liaison
Monogram Biosciences
09.2006 - 04.2008
- Collected, analyzed, and interpreted HIV Resistance and Tropism data. Developed speaker and advisory boards.
Education
Bachelor of Arts - Women’s Studies
University of California, Berkeley
Bachelor of Arts - Physician Assistant
Charles R. Drew University of Medicine and Science
Skills
- Practical implementation in the field
- Market entry strategies
- Curriculum design
- Geographic market penetration
- Market expansion
- Collaborative networking abilities
- Alliance management
- Stakeholder engagement
- Medical study analysis
- Development of medical strategy initiatives
- Digital Technology
- Effective content scheduling
Accomplishments
- Launched all current 3 HIV Prevention drugs in the US Market
- Published data that influenced $200M in funding from CDC for AIDS service organizations.
- Increased drug sales 523% without a sales team.
- Negotiated national contract, placing PrEP in 6000 Walgreens’ pharmacies.
Publications
- Garofalo, Staci Bush, “Addressing LGBTQ Youth in the Clinical Setting.” Fenway Guide to Lesbian, Gay, Bisexual & Transgender Health 1st Edition,75, 2007.
- Pallela, F, Fisher M, Tebas P, ShambaWu D, Ruane P, Flamm J, Wang H, Porter D, De-Oertel S, Frailich T, Bernstein M, Bush S. “SPRINT: Switching to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Maintains HIV-1 Suppression at Week 48.” Poster American Conference for the Treatment of HIV, Denver, CO March 2013.
- Bush S, Cohen C, Arribas J, Henry K, Bloch M, Tonwer W, Wang H, Shae A, De-Oertel S, Frailich, T. “STaR Study: Single Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcome.” Poster, United States Conference on AIDS 2013, New Orleans, LA September 2013.
- Hodder S, Feinberg J, Mera R, Bush S, Rawlings MK. “Regional differences in the utilization of Truvada for PrEP.” Abstract ACTHIV10. American Conference for the Treatment of HIV, Denver, CO, May 2014.
- Bush S, Keglovitz K, Rawlings MK, Mera R. “Age Differences in the Utilization of Truvada for HIV Pre-exposure Prophylaxis (PrEP).” Poster. American Association of Physician Assistants IMPACT, Boston, MA, May 2014.
- Bush S, Rawlings MK, Ng L, Mera R. “Regional Differences in the Utilization of Truvada for PrEP.” Poster 353, 9th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, June 2014.
- Mera RM, Ng L, Magnuson D, Bush S, Rawlings MK. “Changes in the Characteristics of PrEP users in the US before and after Truvada for PrEP approval.” Abstract TUPE087, 20th International AIDS Conference, Melbourne, Australia, July 2014.
- Flach S, Landovitz R, Giler RM, Ng L, Magnuson D, Wooley Bush S, Rawlings K. “Two years of Truvada for pre-exposure prophylaxis utilization in the US.” Poster, 19th, HIV Drug Therapy, Glasgow, UK, November 2014.
- Bush S, Ng L, Magnuson D, Piotnowsky D, Mera Giler, R. “Significant Uptake of Truvada for Pre-exposure Prophylaxis (PrEP) Utilization in the US in Late 2014 – 1Q2015.” Oral abstract #724, IAPAC Treatment, Prevention, and Adherence Conference, Miami, FL, June 2015.
- MacCannell T, Bush S, Verma S, Shvachko V, Rawlings K, Mera R. “Validation of a Truvada for PrEP algorithm using an Electronic Medical Record.” Poster TPEC521, 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention, Vancouver, Canada, July 2015
- Bush S, Magnuson D, Rawlings MK, Hawkins T, McCallister S, Mera Giler R. “Racial Characteristics of FTC/TDF for Pre-Exposure Prophylaxis Users in the US.” Oral abstract #2651, ASM Microbe 2016, Boston, MA, June 2016.
- Bush S, Rawlings K, Magnuson D, Lugo-Torres D, Martin P, Mera R. “Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis in the US by Gender: 2013-102016. Oral abstract, HIV Drug Therapy 2016, Glasgow, Scotland October 2016.
- Adams B, Balderson B, Brown K, Bush S, Packett B. “Who Starts the Conversation and Who Receives Preexposure Prophylaxis (PrEP)? A Brief Online Survey of Medical Providers’ PrEP Practices.” Health Education & Behavior 1–7 2018 Society for Public Health Education.
- Nguyen C, Hawkins T, Anderson J, Bush S, McCallister S, Mera R. “Utilization of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) for HIV Pre-Exposure Prophylaxis (PrEP) in the United States by Age, Gender and Ethnicity: 2014 – 2017.” IAS 2019, Mexico City, Mexico, July 2019
- Mera R, Bush S, Hawkins T, Das M, Asubonteng J, McCallister S. “Impact of PrEP and TasP on Incidence of HIV Diagnoses in 48 Highest-Burden US Areas” (ID 2860), Conference on Retroviruses and Opportunistic Infections (CROI) 2020.
- DeJesus E, Halperin J, Brair I, Daar E, Stephens J, Shao Y, Zhong L, Ebrahim R, Bush S, Anderson J, Das M, McCallister S, Burack J, Inadiorio M, Crofoot G. “DISCOVER: 96-Week Follow-up of Black and Hispanic/Latinx Study Participants” (ID 4033), Conference on Retroviruses and Opportunistic Infections (CROI), 2020.
- Oglesby G, Germain G, Laliberte F, Bush S, Swygard H, MacKnight S, Hitts A, Dub M “Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US” ID Week 2021.
- Sullivan P, Mera-Giler R, Bush S, Shvachko V, Sarkodie E, O’Farrell D, Dubose S, Magnuson D. “Claims-Based Algorithm to Identify Pre-Exposure Prophylaxis Indications for Tenofovir Disoproxil Fumarate and Emtricitabine Prescriptions (2012-2014): Validation Study”. JMIR Form Res 2024;8:e56514. URL: https://formative.jmir.org/2024/1/e56514
Timeline
Senior Director, Virology Scientific Collaboration
Gilead Sciences
01.2023 - Current
Senior Medical Director, HIV Prevention
ViiV Healthcare
12.2020 - 03.2022
Global Executive Director for PrEP, Medical Affairs
Gilead Sciences
04.2020 - 12.2020
Global Senior Director, Medical Affairs
Gilead Sciences
02.2019 - 04.2020
Global Director for Medical Education and Learning & Development, Access Operations and Emerging Markets
Gilead Sciences
08.2017 - 02.2019
Director, Medical Affairs, Truvada and Truvada for PrEP
Gilead Sciences
05.2015 - 08.2017
Associate Director, Medical Affairs
Gilead Sciences
05.2013 - 05.2015
Medical Science Liaison
Gilead Sciences
05.2010 - 05.2013
Medical Director
Harrow Health Center
01.2010 - 06.2010
Physician Assistant
Swedish Covenant Hospital
03.2009 - 01.2010
HIV Director
Clinical Care Options
04.2008 - 01.2009
Medical Science Liaison
Monogram Biosciences
09.2006 - 04.2008
Bachelor of Arts - Physician Assistant
Charles R. Drew University of Medicine and Science
Bachelor of Arts - Women’s Studies
University of California, Berkeley